Synthetic lethality-an interaction between two genetic events through which the co-occurrence of these two genetic events leads to cell death, but each event alone does not-can be exploited for cancer therapeutics 1 . DNA repair processes represent attractive synthetic lethal targets, because many cancers exhibit an impairment of a DNA repair pathway, which can lead to dependence on specific repair proteins 2 . The success of poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors in cancers with deficiencies in homologous recombination highlights the potential of this approach 3 . Hypothesizing that other DNA repair defects would give rise to synthetic lethal relationships, we queried dependencies in cancers with microsatellite instability (MSI), which results from deficient DNA mismatch repair. Here we analysed data from large-scale silencing screens using CRISPRCas9-mediated knockout and RNA interference, and found that the RecQ DNA helicase WRN was selectively essential in MSI models in vitro and in vivo, yet dispensable in models of cancers that are microsatellite stable. Depletion of WRN induced double-stranded DNA breaks and promoted apoptosis and cell cycle arrest selectively in MSI models. MSI cancer models required the helicase activity of WRN, but not its exonuclease activity. These findings show that WRN is a synthetic lethal vulnerability and promising drug target for MSI cancers.
1
, Gad Getz 1, 6 , Sandy Chang 4, 8, 9 , todd r. Golub 1, 10, 11 , Aviad tsherniak * Synthetic lethality-an interaction between two genetic events through which the co-occurrence of these two genetic events leads to cell death, but each event alone does not-can be exploited for cancer therapeutics 1 . DNA repair processes represent attractive synthetic lethal targets, because many cancers exhibit an impairment of a DNA repair pathway, which can lead to dependence on specific repair proteins 2 . The success of poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors in cancers with deficiencies in homologous recombination highlights the potential of this approach 3 . Hypothesizing that other DNA repair defects would give rise to synthetic lethal relationships, we queried dependencies in cancers with microsatellite instability (MSI), which results from deficient DNA mismatch repair. Here we analysed data from large-scale silencing screens using CRISPRCas9-mediated knockout and RNA interference, and found that the RecQ DNA helicase WRN was selectively essential in MSI models in vitro and in vivo, yet dispensable in models of cancers that are microsatellite stable. Depletion of WRN induced double-stranded DNA breaks and promoted apoptosis and cell cycle arrest selectively in MSI models. MSI cancer models required the helicase activity of WRN, but not its exonuclease activity. These findings show that WRN is a synthetic lethal vulnerability and promising drug target for MSI cancers.
Defects in DNA mismatch repair (MMR) promote a hypermutable state with frequent insertion and/or deletion mutations that occur in nucleotide repeat regions-which are known as microsatellites 4 . This class of hypermutations-MSI-contributes to occurrence of several cancers, predominantly in colon (15%) 4 , gastric (22%) 5 , endometrial (20-30%) 6 and ovarian (12%) 7 cancers. MSI can arise from Lynch syndrome 4 , which is caused by germline mutations in the MMR genes MSH2, MSH6, PMS2 or MLH1. More commonly, MSI cancers arise after somatic MMR inactivation, typically through hypermethylation of the MLH1 promoter 4 . Although MSI has been associated with notable responses to immune checkpoint blockade, 45-60% of such cancers do not respond to immune checkpoint blockade, and the use of immune checkpoint blockade can be limited by toxicity 8, 9 . Thus, novel therapies are needed for tumours with MSI.
Hypothesizing that MSI and MMR deficiency may create vulnerabilities, we analysed two independent large-scale cancer dependency datasets, project Achilles and project DRIVE, for genes that are selectively essential in cancer cells with MSI (Fig. 1a) . Project Achilles screened 517 cell lines with a genome-scale CRISPR-Cas9 library and project DRIVE analysed 398 cell lines using an RNA interference library to define genes that were essential for proliferation and survival of individual cancer cell lines 10, 11 . We ascertained MSI status using next-generation sequencing 12 to quantify the number and fraction of deletions that were located within microsatellite regions, identifying three groups: MSI, microsatellite stable (MSS) and indeterminate lines ( Fig. 1b and Supplementary Table 1 ). These classifications were highly concordant with PCR-based MSI phenotyping 13 and with predicted MMR deficiency (Extended Data Fig. 1a ). In total, 51 unique MSI and 541 unique MSS cell lines (excluding those lines marked as indeterminate) were represented by one or both screening datasets.
Projects Achilles (using CRISPR-Cas9) and DRIVE each independently identified WRN, which encodes a RecQ DNA helicase, as the top preferential dependency in MSI compared to MSS cell lines (Q = 4.8 × 10 −24 and 1.5 × 10
, respectively; Fig. 1c ). These findings remained true with PCR-based MSI classifications (Extended Data Fig. 1b) . By contrast, none of the four other RecQ DNA helicases were preferentially essential in MSI cell lines (Extended Data Fig. 1c) . We then evaluated MSI as a biomarker for WRN dependency, demonstrating that the MSI-WRN relationship compared favourably to other strong biomarkers for vulnerabilities such as the relationships between activating KRAS and BRAF mutations and KRAS and BRAF dependencies, respectively (Extended Data Fig. 1d, e) .
MSI is most commonly observed in colorectal, endometrial, gastric and ovarian cancers. MSI cell lines from these four lineages (n = 37) showed greater dependence on WRN than their MSS counterparts (n = 91; P = 4.2 × 10 −13 , Wilcoxon rank-sum test; Extended Data Fig. 2a ). We also identified 14 MSI cell lines from lineages in which MSI was less common (six leukaemia lines, two prostate cancer lines and single models of other lineages). However, these MSI cell lines were distinct and contained a median 0.56-fold fewer deletion mutations in microsatellite regions compared to typical lineages (P = 1.7 × 10 Table 1 ). Correspondingly, the specificity of MSI as a biomarker for WRN dependency was improved by delineating MSI within MSI-predominant lineages (Extended Data Fig. 1d , e). These observations suggest that WRN dependency is not simply a result of MMR deficiency but may require specific lineages and/or a stronger mutation phenotype. Indeed, WRN dependency correlated with the number of microsatellite deletions within all MSI cell lines and in MSIpredominant lineages (Spearman's ρ = −0.74, n = 54, P < 2.2 × 10
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Spearman's ρ = −0.57, n = 37, P = 3.3 × 10 −4 , respectively; Extended Data Fig. 2c, d ).
To further assess WRN dependency, we validated three single-guide RNAs (sgRNAs) that targeted WRN using immunoblots (Extended Data Fig. 3a ) and evaluated WRN knockout in five MSS and five MSI cell lines, all of which were from MSI-predominant lineages, with an eight-day viability assay. Effects of WRN knockout were comparable to 'pan-essential' controls in MSI cell lines. WRN silencing in MSS models instead approximated negative controls, in which intergenic regions were targeted (Fig. 2a) . Similarly, WRN depletion impaired the viability of MSI cells despite negligible effects in MSS cells in a 10-day competitive growth assay (Extended Data Fig. 3b ). Complementing these CRISPR−Cas9 data, WRN silencing with short hairpin RNA (shRNA) impaired cell viability in MSI, but not MSS, cells (Extended Data Fig. 3c, d ). To validate that these phenotypes were attributable to WRN inactivation, we developed an sgRNA that targets a WRN exonintron junction (WRN EIJ sgRNA), which silenced endogenous WRN, but not exogenous WRN cDNA (Fig. 2b) . Correspondingly, WRN cDNA rescued Cas9-expressing KM12 cells from WRN EIJ sgRNA, but not WRN sgRNA 2, which targets endogenous and exogenous WRN (Fig. 2c) . These data indicate that the viability loss in MSI cells is attributable to WRN inactivation.
These findings suggest that WRN dependence with MSI could be exploited by WRN inhibition. WRN functions as both a 3′-5′ exonuclease and 3′-5′ helicase in processes such as DNA repair, DNA replication and telomere maintenance 14, 15 . To determine which enzymatic function is essential, we attempted to rescue WRN EIJ sgRNA using exonuclease-dead (E84A), helicase-dead (K577M) or dually exonuclease-and helicase-dead (E84A/K577M) versions of WRN cDNA 14 in KM12 cells. Exonuclease inactivation did not attenuate rescue, suggesting this function is dispensable. By contrast, helicase inactivation prevented rescue (Fig. 2b, c) , indicating that the helicase domain is a candidate therapeutic target.
Next, we validated WRN dependency in vivo using xenografts of KM12 cells transduced with doxycycline-inducible shRNAs that target WRN (WRN shRNA 1) or control (WRN-C911 shRNA 1) in which nucleotides 9-11 of WRN shRNA 1 were mutated to the complementary nucleotides, thus maintaining the 'seed' sequence associated with shRNA off-target effects 16 . Induction of WRN shRNA 1 but not WRN-C911 shRNA 1 significantly impaired tumour growth (Fig. 2d) . We observed substantial depletion of WRN after induction of WRN shRNA 1 in vivo. However, WRN levels recovered by three weeks (Fig. 2e) , mirroring tumour growth recovery, suggesting that WRN re-expression was required to overcome induction of WRN shRNA 1. We further demonstrated that an shRNA that targets WRN impaired the viability of a newly generated patient-derived organoid that was generated from a colon cancer with MSI ( Fig. 2f, g ). By demonstrating the synthetic lethal relationship in vivo and in a patient-derived model, these data support that WRN is potential a therapeutic target for cancers with MSI.
To pursue the basis of WRN dependency, we first performed cell cycle analyses. WRN silencing reduced the proportion of MSI cells in S phase and increased the number of cells in G1 or G2/M phases, suggesting cell cycle arrest at either G1 or G2/M phases (Extended Data  Fig. 4a, b) . Furthermore, analyses of annexin V and propidium iodide staining show the induction of apoptosis and cell death in MSI cells after WRN silencing (Extended Data Fig. 4a, c, d ). By contrast, MSS cell lines showed no significant evidence of increased cell cycle arrest nor cell death after WRN silencing.
Consistent with the cell cycle and apoptosis assays, mRNA-sequencing analysis of WRN silencing in MSI cells revealed downregulation of genes associated with G2/M checkpoint progression and E2F target signatures, and upregulated signatures of apoptosis. This analysis additionally revealed p53 activation in WRN-depleted MSI cells (Fig. 3a) . Immunofluorescence imaging of proteins in MSI models after WRN silencing showed an increase in phosphorylated (phospho-)p53 (S15), which indicates activation of p53 17 . Letter reSeArCH substantially weaker changes in phospho-p53 intensity in WRNdepleted MSS models (P < 2 × 10
, contrast test of mean fold change in MSS versus MSI lines; Fig. 3b , c and Extended Data Fig. 5a, b) . WRN depletion in TP53 wild-type MSI cells increased protein levels of the cyclin-dependent kinase inhibitor p21, which is another indication of p53 activation. By contrast, there were significantly weaker changes in p21 expression after WRN silencing in MSS and TP53-mutant MSI cells (P < 2 × 10
, fold change in MSI TP53 wild-type versus MSS or TP53-null cells; Extended Data Fig. 5c-f) . We then re-evaluated our dependency data, stratifying by MSI and p53 status. Whereas p53-intact MSI cell lines (n = 23) were more sensitive to WRN loss than their p53-impaired (n = 13) counterparts (P = 0.02, Wilcoxon ranksum test; MSI cell lines from lineages in which MSI were common only), both wild-type and mutant TP53 MSI cell lines were dependent on WRN (Extended Data Fig. 5g ). These data suggest that although WRN loss leads to p53 induction, p53 activity contributes to, but is not solely responsible for, WRN dependence.
The finding of increased p53 (S15) phosphorylation, a phosphorylation target of DNA-damage response kinases ATR and ATM
17
, suggested that WRN loss with MSI leads to DNA damage. This hypothesis is consistent with the roles of p53 and WRN in responding to DNA damage and preserving DNA integrity 15, 17 . Indeed, biallelic germline inactivation of WRN causes Werner syndrome, which is characterized by premature ageing and an increased incidence of cancer due to impaired DNA damage repair and telomeric shortening, which leads to chromosomal aberrations 15 . Next we show that WRN silencing in MSI, but not MSS, cells substantially increased γH2AX and 53BP1 foci, which are markers of double-stranded DNA breaks (DSBs) (Fig. 4a-c and Extended Data Fig. 6a-h ). These findings were corroborated by increased formation of phospho-ATM (S1981) foci and CHK2 (T68) phosphorylation, which are indicative of DSB responses that are known to activate p53 and anti-proliferative signalling pathways 18 (Extended Data Fig. 7a-e) . We confirmed increased γH2AX in MSI cells treated with an shRNA against WRN in vitro and in vivo, suggesting that DSBs are not just a consequence of CRISPR-Cas9 activity ( Fig. 2e and Extended Data Fig. 7e ). These observations also explain why p53-impaired MSI cells are sensitive to WRN depletion as DSBs are toxic to cells, independent of p53 status 19 .
To evaluate chromosomal integrity with WRN silencing, we examined metaphase spreads of two MSI and two MSS cell lines with telomere fluorescence in situ hybridization (FISH), 96 h after induction of WRN shRNA 1. First, we investigated whether a telomere defect precipitates the synthetic lethal relationship given the role of WRN role in protection of the telomeres 15 . WRN silencing induced DSBs and fragmentation throughout chromosomes in MSI cells, but not in MSS cells. However, we did not observe specific telomeric defects such as increased chromosomal end-to-end fusions or telomeric signal loss. Although we observed many MSI cells with chromosomal fragmentation after WRN silencing, we also identified MSI cells that had only a few DSBs (Fig. 4d, e +Dox -Dox P = 0.47 P = 0.033 P = 0.42 P = 0.02 P = 5 × 10 -5 P = 6 × 10 -8 P = 2 × 10 -3 P = 2 × 10 -8 P = 2 × 10 -7 P = 3 × 10 -6 P = 0.29 P = 6 × 10 -7 P = 9 × 10 -5 P = 0.13 P = 3 × 10 -3 P = 3 × 10 -7 P = 3 × 10 -6 P = 0.44 
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analysed the localization of WRN using immunofluorescence microscopy. After demonstrating the specificity of WRN immunofluorescence staining (Extended Data Fig. 8b ), we observed predominantly dispersed WRN staining across the nucleoplasm in MSI cells, whereas greater co-localization of WRN with the nucleolar marker fibrillarin (Extended Data Fig. 8b-d ) and less nucleoplasmic staining was found in MSS cells. Because WRN has been demonstrated to respond to DNA damage by disseminating from the nucleolus towards the nucleoplasm 20 , these data suggest that WRN is recruited to maintain genomic integrity in MSI cells.
We next evaluated the relationship between MMR deficiency and WRN dependency. We first investigated whether MSI leads to recurrent mutations and inactivation of another gene, creating a dependency on WRN. The second most significant dependency with MSI was RPL22L1, a dependency described in MSI that is attributable to an inactivating mutation of its paralogue, RPL22 11 (Fig. 1c) . Analysing our screening dataset, we found no gene for which the loss could account for the preferential dependency on WRN of cells with MSI (Extended Data Fig. 9a ). We also found no increased dependence on WRN in cell lines with hypermutations that are due to mutations in polymerase epsilon (POLE) 21 (Extended Data Fig. 9b and Supplementary . n indicates the number of cells (treated with Chr.2-2 sgRNA, WRN sgRNA 2, WRN sgRNA 3, respectively) for KM12 (7, 080, 14, 410, 15, 921) , SW48 (15, 329, 9, 491, 13, 196) , SW620 (27, 374, 23, 898, 28, 808) . Representative data from one experiment are shown. All experiments were performed twice, except for experiments in a, which were performed once. Mean log(change in intensity) following WRN knockout compared to control in MSI compared with MSS cells; P < 2 × 10 −16 , contrast test of least-squares means. Mean fold change (calculated as log(change in intensity)): 0.39 (KM12), 0.33 (SW48), −0.10 (SW620). n indicates the number of cells (treated with Chr.2-2 sgRNA, WRN sgRNA 2, WRN sgRNA 3, respectively) for KM12 (3, 029, 8, 880, 6, 887) , SW48 (13, 246, 4, 553, 7, 216) , SW620 (9, 071, 5, 174, 3, 853 DSB accumulation and partially rescued viability from WRN shRNA treatment in a seven-day viability assay (Fig. 4f and Extended Data Fig. 10b ). The rescue was indeed attributable to MMR restoration as CRISPR-Cas9 knockout of MLH1 sensitized HCT116 cells that possess additional Chr.3+5 to WRN silencing and induced DSBs after WRN silencing (Extended Data Fig. 10c, d ). Longer-term clonogenic assays with HCT116 cells established that rescue of WRN dependency is modest with MMR restoration, but abolished with MLH1 knockout (Extended Data Fig. 10e, f) .
These data suggest that MMR deficiency alone contributes to the synthetic lethal interaction that we found, although it does not fully explain this interaction, suggesting that genomic lesions that accumulate with MSI promote WRN dependence. The potential relevance of accumulation of genomic lesions is consistent with our observation that MSI cells with fewer microsatellite deletions are less dependent on WRN. Accumulating MSI defects could cooperate with MMR deficiency to form genomic structures that require WRN to resolve. Such structures could include insertion-deletion loops 23 and/or displacement loops (D-loops) between homeologous DNA sequences 24, 25 , which are known substrates for MMR machinery. Indeed, MMR deficiency in yeast creates a dependency on Sgs1, which is a homologue of WRN and BLM, to resolve homeologous D-loops that are normally rejected by MMR 26 . Beyond the potential role of WRN in preventing DNA damage, loss of WRN in non-homologous end joining and/or homologous recombination could further contribute to the accumulation of DSBs 15 .
Our observations reveal that WRN inactivation induces DSBs and activates DSB responses to promote cell death and cell cycle arrest preferentially in MSI cells. Although WRN and other DNA helicases have been nominated as therapeutic targets 27 , our study highlights WRN as a synthetic lethal target in cancer cells with MSI, defining a population in which a WRN-based therapeutic could be used. Further studies will be needed to further explore the intersecting roles of MMR deficiency and genomic lesions in MSI with WRN dependence. Although systemic WRN inhibition could induce complications akin to Werner syndrome, the manifestations of this syndrome require decades to emerge 28 , suggesting that therapeutic benefits would greatly outweigh risks. Results from this study and the companion study by Behan et al. 29 support efforts aimed at designing WRN helicase inhibitors to exploit WRN dependency in MSI cancers. More broadly, our findings highlight the power of large-scale cancer profiling efforts [10] [11] [12] 29, 30 to identify cancer vulnerabilities and therapeutic biomarkers, illustrating how a cancer dependency map 11, 30 can accelerate the development of precision therapy for patients with cancer.
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METHODS
Genetic dependency data. CRISPR dependency data were taken from the 18Q4 Avana dataset 31 . These data contain gene dependencies estimated for each gene and cell line using the CERES algorithm 10 . RNA interference (RNAi) dependency data were derived from project DRIVE (Novartis) 11 and were reprocessed using the DEMETER2 algorithm 32 , which can be downloaded from the DEMETER2 figshare repo 33 . For some analyses (for example, Extended Data Figs. 1e, 2c, d, 5g, 9b), we computed aggregate WRN dependency scores for each cell line by averaging together RNAi and CRISPR dependency scores (which are both normalized so that the median score of pan-essential genes is set at −1) 10, 34 . For Extended Data Figs. 1c, 2a, 5g, 9b, the lower and upper parts of the boxes correspond to first and third quartiles (25th and 75th percentiles). The upper and lower whiskers extend to the largest and smallest value within 1.5× the interquartile range (IQR) from the box. Gene dependency scores are normalized such that a value of 0 represents the median dependency score of negative control genes and −1 represents the median dependency score of sgRNAs that target pan-essential genes. Genomics data. Cancer cell line genomic data used in the analysis, including genelevel mRNA expression, gene-level relative copy number and mutation calls, were taken from the DepMap 18Q4 data release 12, 34 . Protein abundance data of reversephase protein arrays (RPPA) were taken from the Cancer Cell Line Encyclopedia (CCLE) 10, 12, 34 . All cell line omics data can be downloaded at DepMap (https:// depmap.org/portal/). Cell line annotations. Annotations of primary disease site for each cell line can found in the DepMap 18Q4 data release. The functional status of TP53 in 966 cell lines was annotated based on a combination of the nutlin-3 sensitivity of the cell lines (Genomics of Drug Sensitivity in Cancer; http://www.cancerrxgene.org) and Cancer Target Discovery and Development (CTD2 -https://ocg.cancer.gov/programs/ctd2/data-portal) data sets, along with a p53 target gene expression signature computed from CCLE data 35 . Microsatellite classification. MSI classifications were obtained from phase II of the CCLE project 12 . These classifications were based on the total number of deletions detected in each cell line, and the fraction of deletions in microsatellite regions, using several different data sources (CCLE whole-exome sequencing, CCLE whole-genome sequencing, CCLE hybrid capture and Sanger whole-exome sequencing datasets). These features were then used to classify each cell line as MSI, MSS or indeterminate. Unless otherwise indicated, our analysis excluded cell lines classified as indeterminate. When plotting the number of microsatellite deletions and fraction of deletions in microsatellite regions ( Fig. 1b and Extended Data Fig. 1a) , we averaged these values across the data sources available for each cell line after normalizing for systematic differences between data sources. Specifically, we used linear regression models to estimate and remove scale and offset differences between data sources so that the normalized number of deletions (and number of deletions in microsatellite regions) measured in each data source was equal on average. These normalized average numbers of microsatellite deletions and fraction of deletions in microsatellite regions are provided in Supplementary Table 1 . MMR status. MMR status was determined based on omics data for the genes MSH2, MSH6, MLH1 and PMS2. For each gene, we determined whether it was mutated (any detected mutation classified as deleterious), deleted (relative log 2 (-copy number) < −1) or lowly expressed (log 2 (mRNA expression in transcripts per million) < 1). A gene was classified as inactivated if any of the above criteria were met, and cell lines in which any of these MMR genes were inactivated were classified as having 'MMR loss' . The MMR status for cell lines for which we did not have either gene expression or copy number data available were classified as 'NA' . In addition, we annotated MSI cell lines as having low protein expression of MSH2 and MSH6 if they had protein levels <−1 in the RPPA data (Supplementary Table 1 ). However, RPPA data were not used for calling MMR loss, as we were missing RPPA data for many cell lines, and MMR loss was detectable from other omics data in most cases. We also classified the mutation status of POLE for all cell lines as 'damaging' , 'hotspot missense' or 'other' using the 'Variant_Annotation' column of the CCLE mutation file. Differential dependency analysis. Genes that were preferentially dependent in MSI compared to MSS cell lines were identified using linear modelling performed in parallel across genes using the R package Limma 36 . We estimated the difference in mean dependency between MSS and MSI cell lines for each gene, and associated P values were derived from empirical-Bayes-moderated t-statistics. Q values were computed using the Benjamini-Hochberg method 37 . Dependency and biomarker analysis. To compute the predictability of gene dependencies from different biomarkers, we first called each cell line as dependent or not, by thresholding the average of the CRISPR-and RNAi-based dependency scores at a value of −0.5. We then computed the positive predictive value and sensitivity for each biomarker-dependency relationship. WRN dependency was predicted using MSI status either across all cell lines or within common-MSI lineages only. For comparison, we performed equivalent analysis on several canonical biomarker-dependency relationships: KRAS dependency was predicted by KRAS hotspot missense mutations, BRAF dependency was predicted by BRAF hotspot missense mutations, MDM2 dependency was predicted by TP53 wild-type versus mutant status (including damaging, hotspot missense and other non-silent mutations), PIK3CA dependency was predicted by PIK3CA hotspot missense mutations, ERBB2 dependency was predicted by ERBB2 amplification (log 2 (relative copy number) > 2), NRAS dependency was predicted by NRAS hotspot missense mutations and CTNNB1 dependency was predicted by APC damaging mutations. Assessing potential WRN synthetic lethality. To assess whether loss of function of any particular gene could account for WRN dependency, we determined the functional status of each gene (loss or not) in the same way as described above for MMR gene loss. For each gene, we then used a linear regression model to assess the contribution of both MSI status and loss of the gene to predicting WRN dependency (average of CRISPR and RNAi dependency scores). In Extended Data  Fig. 9a , we plot the linear model coefficients, and associated P values, for MSI status accounting for loss of each gene. mRNA sequencing. Cas9-expressing cells (SW48 and OVK18) were lentivirally transduced with the following sgRNAs: Chr.2-2 sgRNA, WRN sgRNA 2 and WRN sgRNA 3 (sequences provided below). Cells were selected with puromycin and RNA was purified 72 h after transduction. This was performed in duplicate before cDNA library preparation and subsequent RNA sequencing using the Illumina NextSeq 500 performed by the Molecular Biology Core Facilities at the DanaFarber Cancer Institute (DFCI). This experiment was performed once with two biological replicates. Differential expression analysis. We first excluded genes that had less than one count per million in more than half of the samples. The weighted trimmed mean of M-values 38 method was used to normalize the library size of each sample, using the calcNormFactors function from the R package edgeR 39 . To estimate the fold change effect of WRN knockout (calculated as log(knockout/control)) on each gene in each cell line, we used the R package Limma 36 . Specifically, we fit a linear model for the expression of each gene, using cell line and sgRNA (WRN versus control) as covariates. Read count data were transformed using the Limma function 'voom' before model fitting, in order to model the mean-variance relationship of the log(counts) data 40 . We then extracted fold change effect sizes and empirical-Bayes-moderated t-statistics for the WRN knockout effect for each gene and cell line. Gene set enrichment analysis (GSEA) 41 was run to test for gene sets that were up-or downregulated in each cell line after WRN knockout. In particular, we used the R package fgsea 42 to estimate normalized enrichment statistics, and associated P values, for each gene set in the Hallmark Collection from the Molecular Signatures Database 43 . The GSEA algorithm was run using t-statistics as the gene-level statistics, 1 million random permutations for each cell line tested, and a 'GSEA parameter' of 1. Cell lines and reagents. The ES2, OVK18, SW620, SW837, KM12, SW48, GCIY, SNU1, HEC50B and SNGM cell lines were collected by the CCLE before distribution for our use. The sources of the aforementioned cell lines can be found at DepMap.org and are as follows. The ES2, SW620, SW837, SNU1 and SW48 cell lines were originally obtained from the American Type Culture Collection (ATCC). The KM12 cell line was originally obtained from an academic laboratory and can be obtained as part of the NCI-60 cell lines. The GCIY and OVK18 cell lines were originally obtained from the RIKEN Cell Bank. The SNGM and HEC50B cell lines were originally obtained from the Health Science Research Resources Bank. Their identities were confirmed by SNP microarray. The HCT116 cell line and its various derivatives were provided by C. R. Boland, A. Goel and M. Koi 22 . The aforementioned cell lines can be obtained from their respective sources. All cell lines were grown in medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 μg ml ; Gibco) unless otherwise stated. KM12, SW48, SW837, ES2, and SNU1 cells were cultured in RPMI-1640 (Gibco); OVK18 cells were cultured in MEMα; GCIY cells were cultured in MEMα supplemented with 15% FBS; SW620 cells were cultured in Leibovitz's L-15 (Gibco); SNGM cells were cultured in Ham's F12 with 20% FBS (Gibco); HEC50B cells were cultured in EMEM (ATCC) supplemented with 15% FBS; HCT116 cells were cultured in McCoy's 5A (Gibco). Stable Streptococcus pyogenes Cas9-expressing cell lines generated by lentiviral transduction of the pXPR_BRD111 construct were from project Achilles 10 . pXPR_BRD111 is available from Addgene (plasmid 78166).
CCLF_CORE_0001_T was obtained from a 58-year-old female patient with stage II MSI-H colon carcinoma (determined by loss of MLH1 and PMS2 with MLH1 promoter methylation using immunohistochemistry). All samples were obtained with informed consents of the patients at the DFCI. All procedures were conducted under a protocol approved by the DFCI Institutional Review Board. Samples were collected by translational research staff and labelled with a unique identifier before samples were processed and analysed in the laboratory. Per the protocol, the link to protected health information was maintained within a database with access limited to select research staff. Samples were handled according to the medical ethical guidelines described by the Dana-Farber/Harvard Cancer
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Center Office for Human Research Studies. Patient tumour resections were placed in a sterile conical tube containing DMEM medium (Thermo Fisher Scientific, 11995073) with 10% FBS (Sigma-Aldrich, F8317), 1% penicillin-streptomycin (Thermo Fisher Scientific, 15140163), 10 μg ml −1 of gentamicin and 250 ng ml
fungizone on wet ice during transport from the operating room to the research laboratory. Resections were placed in a 15-ml conical flask with 5 ml DMEM medium, 10% FBS, 1% penicillin-streptomycin and the digestion enzymes regular collagenase 1 ml (StemCell, 07912) and dispase 1 ml (StemCell Technologies, 07913). The flask was placed on a rotator and incubated at 37 °C for 1 h. The cells were then centrifuged at 1,000 r.p.m. for 5 min. Cell pellets were resuspended and later embedded into Matrigel (Corning, 356231) as per the previous published protocol 44 . Colorectal carcinoma organoids were passaged using iced-cold PBS and Gibco TrypLE Express (Thermo Fisher Scientific, 12604039) when the cells reached 80-90% confluence. CCLF_CORE_0001_T will be deposited to a thirdparty distributor at a later date.
All cell lines tested negative for mycoplasma. Generation of ectopic WRN cDNA-expressing cell lines. The catalytically active version, exonuclease-dead (E84A), helicase-dead (K577M) and dually exonuclease and helicase-dead (E84A/K577M) versions of WRN cDNA were a gift from R. J. Monnat (Addgene, plasmids 46038, 46036, 46035 and 46037, respectively). The missense mutant forms of WRN have been previously demonstrated to lack their indicated enzymatic activity 14 . The WRN sequence was cloned into a modified lentiviral expression vector, pLX_TRC209, under an EF1A promoter and modified to contain a neomycin-selectable marker. Sanger sequencing of the vectors and genomic DNA after integration were performed to confirm sequence identity. Lentivirus was produced as described below and transduced into dually Cas9-Firefly-luciferase-expressing KM12 cells to create stable ectopic WRN cDNA-expressing cell lines. Lentiviral production. Lentiviral production was performed using HEK293T cells as described on the GPP portal (https://portals.broadinstitute.org/gpp/public/). sgRNAs. sgRNAs used in the validation studies were designed using the Broad Institute Genetic Perturbation Platforms sgRNA Designer (https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design). sgRNAs targeting WRN include WRN sgRNA 1 (target sequence GTAAATTGGAAAACCCACGG), WRN sgRNA 2 (ATCCTGTGGAACATACCATG), WRN sgRNA 3 (GTAGCAGTAAGTGCAACGAT). sgRNA targeting the exon-intron junction (WRN EIJ sgRNA) were designed using the DESKGEN Cloud tool (https://www. deskgen.com/landing/cloud.html). The target sequence for WRN EIJ sgRNA is AGCACGTACATAAGCATCAG. Two negative controls targeting intergenic sites on chromosome 2 were used: Chr.2-2 sgRNA (GGTGTGCGTATGAAGCAGTG) and Chr.2-4 sgRNA (GCAGTGCTAACCTTGCATTG). Two pan-essential controls targeting POLR2D (AGAGACTGCTGAGGAGTCCA) and MYC (ACAACGTCTTGGAGCGCCAG) were used. sgRNAs were inserted in the pXPR_ BRD003 lentiviral vector and inserts were verified by Sanger sequencing. sgRNAs targeting MLH1 include MLH1 sgRNA 1 (TTTGGCCAGCATAAGCCATG) and MLH1 sgRNA 2 (GCCAGCACATGGTTTAGGAG). sgRNAs targeting MLH1 were inserted in the pXPR_BRD051 lentiviral all-in-one vector, which also expresses Cas9. shRNAs. shRNA targeting WRN were chosen from project DRIVE. shRNAs targeting WRN include WRN shRNA 1 (CAGCACTGCCAATGGTTCCAA) and WRN shRNA 2 (GCCTTAACAGTCTGGTTAAAC). Positive pan-essential controls include PSMD2 shRNA (CGCCAGTTAGCTCAATATCAT) a n d R P S 6 s h R NA ( C C G C C AG TAT G T T G TA AG A A A ) . R F P shRNA (CTCAGT TCCAGTACGGCTCCA), WRN-C911 shRNA 1 (CAGCACTGGGTATGGT TCCAA) and WRN-C911 shRNA 2 (GCCTTAACTCACTGGTTAAAC) were used as negative controls. These shRNAs were inserted into pLKO.1 puro (Addgene, 8453) for constitutive expression and pRSITEP-U6Tet-(xx)-EF1-TetRep-2A-Puro (Cellecta, SVSHU6TEP-L) for doxycycline-inducible shRNA expression. All in vitro experiments used 0.2 μg ml −1 of doxycycline for induction of shRNAs. Immunoblotting. For immunoblotting, cells were lysed in RIPA buffer (SigmaAldrich) supplemented with complete Protease Inhibitor Cocktail (Roche, 11697498001) and a Halt Phosphatase Inhibitor Cocktail (Thermo Fischer Scientific, 78428). For etoposide and hydroxyurea treatment (Fig. 4a) , cells were treated with 10 μM etoposide and 1 mM hydroxyurea, respectively, 6 h before collection. Lysates were fractionated in 4-12% Bis-Tris gels (Invitrogen), which was then transferred to PVDF membranes (Immobilon-FL PVDF Millipore, IPFL00010) and blocked for an hour with Odyssey Blocking Buffer (PBS) (LI-COR Biosciences, 927-40000). Types of primary antibodies and the dilutions used for immunoblotting were as follows: anti-phospho-CHK2 (T68) (R&D Systems, AF1626, 1:400); anti-total CHK2 (Cell Signaling Technology, 3440, 1:1,000); anti-γH2AX (Cell Signaling Technology, 9718, 1:1,000); anti-GAPDH (Cell Signaling Technology, 5174, 1:1,000); anti-MLH1 (Cell Signaling Technology, 3515, 1:1,000); anti-MSH3 (BD Biosciences, 611390, 1:400); anti-WRN (Novus Biologicals, nb100-472, 1:1,000). We used the following secondary antibodies: goat anti-rabbit IRDye 800CW (LI-COR, 926-32211, 1:5,000), goat anti-rabbit IRDye 680LT (LI-COR, 926-68021), and goat anti-mouse IRDye 800CW (LI-COR, 926-32210). Subsequent steps of immunoblotting were conducted using a near-infrared western blot detection system (LI-COR Biosciences) as per the manufacturer's recommendations. We performed the immunoblots three times except for blots shown in Figs. 2e and 4a and Extended Data Figs. 7e, 10b, d , which were performed twice. Representative results from one experiment are shown. Immunofluorescence. Immunofluorescence experiments were conducted essentially as described previously 45 ) cells for SW620, KM12, SW48, ES2 and OVK18 cells, respectively. Cells were fixed and stained 2 days later. Micrographic images were acquired using either epifluorescence microscopy ( Fig. 3b and Extended Data Fig. 5a , c, e) or confocal microscopy ( Fig. 4b and Extended Data Figs. 6b, e, g, 7a, c) , which were performed on an Axio Observer. Z1 microscope equipped with an Axiocam 506 monocamera and Apoptome.2 (Zeiss) and a Zeiss LSM 700 laser scanning confocal system equipped with Axio Observer (Zeiss), respectively. These confocal microscopy images represent maximum intensity projections of five consecutive planes with a step size of 0.08 μm. For image quantification, images were acquired using an Opera Phenix High-Content Screening System (PerkinElmer, HH14000000) and analysed using Harmony High Content Imaging and Analysis Software (PerkinElmer, HH17000001). For phospho-p53, p21, γH2AX and phospho-ATM staining, signal intensities in the nucleus of at least 1,000 cells per sample were scored on background-subtracted images and presented as box plots. The lower and upper limits of the boxes represent the 25th and 75th percentiles, respectively, and the bar in the middle of the box represents the median value. The whiskers represent the 1st and 99th percentiles. Outliers are represented as dots. To score the patterns of nuclear staining, cells exhibiting a mean signal intensity of 12,000 or higher (for γH2AX; all cell types) (20,000 or higher for phospho-ATM, except for KM12 and SW48 cells, for which '40,000 or higher' and '10,000 or higher' were used to identify cells with pan-nuclear phospho-ATM staining patterns, respectively) were first separated as cells with a pan-nuclear pattern of staining. For the rest of the cells, the number of foci within the nucleus was scored using a spot-detection program in the software. The relative abundance of cells that showed pan-nuclear staining and the relative abundance of cells that contained a specific number of foci were plotted. The numbers of nuclear foci that were observed in cells expressing the Apple-53BP1-trunc fluorescent marker were scored similarly (Extended Data Fig. 6f, h ). To assess differences between the effects of WRN knockout on immunofluorescence intensity values in MSI versus MSS cell lines, we used a linear model approach. Specifically, linear models were fit to the log(intensity) values with guide and cell line intercept terms. Comparisons of the change in log(intensity) after WRN knockout between cell lines were then obtained using the 'contrast' function of the R package lsmeans 46 . Immunofluorescence analysis of WRN and fibrillarin was performed as previously described 47 . Images were obtained using the Zeiss LSM510 Upright Confocal System (Extended Data Figs 8b, c) . Weighted Pearson co-localization coefficients were calculated by obtaining z-stacks of five representative high-powered fields at 63× magnification and scored using the Zeiss Zen Blue software. Significance was calculated by two-tailed Student's t-test for MSI cell lines compared to lineage-matched MSS cells (Extended Data Fig. 8d) .
Types of primary antibodies and the dilutions used for immunofluorescence were as follows: anti-γH2AX (Millipore Sigma, 05-636, 1:400); anti-p21 (Santa Cruz Biotechnology, sc-6246, 1:100); anti-phospho ATM (S1981) (Millipore Sigma, 05-740, 1:200); anti-phospho-CHK2 (T68) (R&D Systems, AF1626, 1:100); anti-fibrillarin (Abcam, ab5821, 1:500); anti-phospho-p53 (S15) (Cell Signaling Technology, 9284, 1:100); anti-WRN (Sigma-Aldrich, W0393, 1:200).
For all immunofluorescence experiments except for the double staining for WRN and fibrillarin, the secondary antibody was goat anti-rabbit IgG, Alexa Fluor 488 (Thermo Fisher Scientific, A11008) and goat anti-mouse IgG, Alexa Fluor 488 (Thermo Fisher Scientific, A11001), which were used at a 1:200 dilution. For WRN and fibrillarin immunofluorescence experiments, goat anti-mouse IgG, Alexa Fluor 488 (Thermo Fisher Scientific, A-11001) and goat anti-rabbit IgG, Alexa Fluor 555 (Thermo Fisher Scientific, A-21428) were used at 1:1,000 dilution. Following secondary antibody treatment, the nuclei were counterstained with 4′,6-diamidine-2′-phenylindole dihydrochloride (DAPI (Sigma-Aldrich, S9542); 1 μg ml SNU1, were seeded the day before transduction. SNU1 cells-a line grown in suspension-were seeded on the day of transduction with 4 μg ml −1 polybrene. For the adherent cell lines, the medium was changed to medium containing 4 μg ml −1 polybrene. Viral concentrations were predetermined to achieve >90% infection efficiency. Experiments were performed in triplicate by adding the appropriate volume of lentivirus to integrate vectors that encoded the desired sgRNA and the plates were spun at 931g for 2 h at 30 °C. The medium was changed the next day and every 3 days thereafter. Cell viability was assayed using CellTiter-Glo (Promega G7572) at 33 μl per well. Luminescence was read using a PerkinElmer EnVision 2105. Values were normalized to the average values from the negative control sgRNAs for each cell line. Experiments were performed three times. The triplicate results of one representative experiment are shown. Two-way ANOVA was used to test differences between the set of WRN sgRNAs or WRN shRNAs and negative control(s), while modelling individual sgRNA/shRNA differences (Figs. 2a and 4f and Extended Data Fig. 10c ).
For CCLF_CORE_0001_T, 5 × 10 4 cells were seeded into 40 μl Matrigel domes in a 24-well plate in quadruplicate, with two wells with and two wells without 0.2 μg ml −1 of doxycycline. Medium was refreshed every 2-3 days. Nine days after doxycycline treatment, cell viability was assayed by first aspirating the medium, adding 300 μl of CellTiter-Glo 3D (Promega G9681) and incubating at room temperature for 45 min on a shaker. Then, three aliquots of 90 μl were taken from each well and were transferred to a 96-well plate (Corning, 3904) for three technical replicates each from two biological replicates. Luminescence was read as above. Values are presented as the mean ratio of luminescence signal from the doxycycline-treated condition compared to the condition without doxycycline with error bars representing the s.e.m. unless otherwise stated. Two-tailed Student's t-tests were performed between each WRN shRNA and its corresponding seed control shRNA (Fig. 2g) . This experiment was performed twice and we present data from one experiment. Luciferase competitive growth assay. Dual Cas9-Firefly-luciferase-and Renillaluciferase-expressing cells were generated by transduction of Firefly-luciferase cDNA and Renilla-luciferase cDNA, respectively, in a pLX_TRC313 lentiviral expression vector containing a hygromycin-resistance gene. After hygromycin selection, these two versions of the cell line were co-seeded in a 96-well plate at the following densities per well for each version: ES2, 2 × 10 3 cells per well; OVK18, 3 × 10 3 cells per well; SW620, 4 × 10 3 cells per well; KM12, 4 × 10 3 cells per well. The following day, cells were transduced with lentivirus expressing the indicated sgRNA and a puromycin-resistance gene in six replicates. The day following viral transduction, the medium was changed to include puromycin. Cells were split and assayed with the Dual-Glo Luciferase Assay System (Promega) per the manufacturer's recommendations every 3-4 days. Luminescence was determined using the Perkin Elmer EnVision 2105. Values are presented as the ratio of Firefly to Renilla luciferase luminescence signal per condition and normalized to the mean of the corresponding negative control sgRNAs for each cell line. Experiments in Fig. 2c and Extended Data Fig. 3b were performed three times. Two-tailed Student's t-tests were performed when comparing single sgRNAs (Fig. 2c) . Two-way ANOVAs were performed when multiple WRN sgRNAs were compared to negative controls (Extended Data Fig. 3b) . Clonogenic assay. Cells were transduced with lentivirus expressing indicated shRNAs. After 24 h, the medium was replaced with medium containing 2 μg ml 4 cells for ES2, OVK18, SW620, SW837, KM12, SW48 and HCT116 cells, respectively. Cells were subsequently propagated for 2 weeks in puromycin-free medium, which was changed every 3 days. For crystal violet staining, cells were fixed with 10% formalin for 30 min at room temperature and subsequently stained with 250 μl per well of 0.1% crystal violet in 70% ethanol for 30 min at room temperature with constant shaking. To remove unbound crystal violet, cells were washed with deionized water three times for 5 min each. Quantification was performed by extracting the crystal violet dye with 250 μl of 10% acetic acid. Then, 50 μl was transferred into a 96-well format in triplicate. The experiments were performed three times (Extended Data Fig. 3c, d ) or two times (Extended Data  Fig. 10e, f) . Crystal violet absorbance was determined using the Perkin Elmer EnVision 2105. The results of one representative experiment are shown with quantification, which shows the repeat measurements from a single experiment. Twoway ANOVA was performed for Extended Data Fig. 10f Cell cycle analysis. Cas9-expressing cell lines were lentivirally transduced to deliver the desired sgRNAs or shRNAs. Medium was changed the next day to allow for antibiotic selection. Subsequently, 4 days after the lentiviral transduction, cells were labelled with EdU, collected and stained as per the Click-iT Plus EdU Flow Cytometry Assay Kit recommendations. Stained cells were then examined using flow cytometry and results analysed with FlowJo v.10. A representative result of two independent experiments is shown; each experiment was conducted in triplicate. Statistical analysis of the proportion of cells in S phase versus Chr.2-2 sgRNA was calculated by two-way ANOVA (Extended Data Fig. 4b) . Apoptosis assay. Cas9-expressing cell lines were lentivirally transduced to deliver vectors that encoded the desired sgRNAs or shRNAs. Medium was changed the next day without antibiotic selection. Cells were split 4 days after transduction. Then, 7 days after transduction, cells were collected and stained with annexin V− FITC and propidium iodide. Stained cells were then examined with flow cytometry and results analysed with FlowJo. A representative result of two independent experiments is shown; each experiment was conducted in triplicate. Significance was calculated for the sum of the proportions of cells in early apoptosis, late apoptosis and nonapoptotic death categories; in cells expressing a WRN sgRNA compared to cells expressing Chr.2-2 sgRNA (control sgRNA) by two-way ANOVA (Extended Data Fig. 4c, d) . To compare xenograft tumour growth curves across experimental conditions, we used a linear mixed model to describe the percentage increase in tumour volume as a linear function of time, with random slope terms per mouse, and an interaction term between growth rate and experimental conditions. Maximum likelihood models were fit using the R package lme4 48 . Reported P values assessing the significance of interactions between growth rate and experimental conditions were derived using a likelihood ratio test. Tumours were collected at the indicated time points. Experiments in Fig. 2d were conducted once. The immunoblot for this experiment (Fig. 2e) was performed twice from the same protein lysates. Telomere PNA-FISH of metaphase spreads. In brief, 3 × 10 6 cells were plated in 10-cm dishes in the absence of doxycycline. For cells treated with doxycycline, 0.2 μg ml −1 of doxycycline was added and refreshed every 48 h. Then, 96 h after adding doxycycline, cells were treated with 10 μg ml −1 of colcemid for 3 h and then detached with trypsin. Half of the cell pellet was saved for immunoblot analysis. The other half of the cell pellet was treated with a hypotonic solution (60 mM KCl) and fixed with a 3:1 ratio of methanol:acidic acid. Metaphases were spread onto a slide and fixed with 3% formalin. The PNA-FISH probe ((CCCTAA) 3 PNA probe (PNA Bio)) was applied to the slides and denatured at 85 °C for 3 min. The slides were washed with washing solution I (70% formamide, 0.1% Tween-20, 0.1% BSA in 10 mM Tris buffer, pH 7.5) twice and three times with washing solution II (150 mM NaCl, 0.1% Tween-20, 0.1% BSA in 50 mM Tris buffer, pH 7.5). Cy5-ATTCGTTGGAAACGGGA was used to label centromeres. Images were captured with a Nikon Eclipse 80i microscope and processed with the NISElements BR software. In total, 30 to 60 metaphases were analysed for cells of the indicated conditions. Two-tailed Student's t-tests were performed (Fig. 4e) . These experiments were performed twice. Fluorescence-based multiplexed host cell reactivation (FM-HCR) assays. Assays to assess MMR impairment in isogenic HCT116 cells were carried out as previously described 49 . SW620, SW837, HCT116 and its derivatives were collected as a subconfluent population (<85%) and electroporated with FM-HCR reporter plasmids (50 ng pmaxOrange_GG for mismatch repair with 50 ng pmax_mPlum as transfection control or 50 ng pmax_mOrange as undamaged control and 50 ng pmax_mPlum as transfection control) and carrier DNA in a 10-μl volume using Letter reSeArCH the ThermoFisher Neon transfection system (1,200 V, 20 ms, 2 pulses) Fig. 10a) . Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
Source Data for Figs. 2a-g, 3c, 4a , c, e, f and Extended Data Figs. 3a, b, d, 4b-d, 5b,  d, f, 6a, c, d, f, h, 7b, d , e, 8d, 10a-d, f are provided with online version of the paper. mRNA-seq data (shown in Fig. 3a) 
Code availability
Code used for analysis can be found at https://github.com/cancerdatasci/WRN_ manuscript. All materials can be accessed at https://depmap.org/WRN. . n indicates the number of cells treated with Chr.2-2 sgRNA, WRN sgRNA 2, WRN sgRNA 3, respectively, for OVK18 (3,982, 1,143, 2,740) and ES2 (4, 916, 3, 072, 3, 690) . c, p21 immunofluorescence images following sgRNA transduction in colon cell lines (SW620, KM12 and SW48). KM12 is a p53-impaired MSI cell line. Scale bar, 50 μm. d, Nuclear p21 staining per cell. Data were analysed as fold change (log(WRN sgRNA/ control sgRNA)); WRN knockout compared to control in SW48 cells was compared to either SW620 (P < 2 × 10 −16 ; contrast test of least-squares means) or KM12 cells (P < 2 × 10 −16 ; contrast test of least-squares means). Mean = 0.13 (SW48), mean = −0.016 (SW620), mean = −0.032 (KM12). n indicates the number of cells analysed following treatment with Chr.2-2 sgRNA, WRN sgRNA 2, WRN sgRNA 3, respectively, for SW48 (16, 203, 7, 617, 13, 257) , SW620 (7, 278, 13, 768, 11, 576) and KM12 (16, 117, 14, 200, 11, 301) . e, p21 immunofluorescence images following sgRNA transduction in ovarian cell lines. Scale bar, 50 μm. f, Nuclear p21 staining intensity per cell. Data were analysed as fold change (log(WRN sgRNA/ control sgRNA)); WRN knockout compared to control in OVK18 cells was compared to ES2 cells; contrast test of least-squares means; P < 2 × 10 −16 . Mean = 0.157 (OVK18), mean = −0.010 (ES2). n indicates the number of cells analysed following treatment with Chr.2-2 sgRNA, WRN sgRNA 2, WRN sgRNA 3, respectively, for OVK18 (3, 436, 5, 876, 8, 275 ) and ES2 (9, 117, 6, 834, 11, 576) . g, WRN dependency for cells lines classified as MSS (n = 514), MSI from an infrequent MSI lineage (n = 6 and 8 for p53-intact and -impaired), or MSI from an MSI-predominant lineage (n = 23 and 13 for p53-intact and -impaired) and further subclassified by p53 status. ( † compared to ‡), P = 2.8 × 10 −8 ( † compared to §). b-f, Representative data from one experiment are shown. All experiments were conducted twice except in a, for which experiments were conducted three times.
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For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code
Data collection
No software was used for collection of genomic data.
Luminescence and absorbance measurements were obtained by the Perkin Elmer EnVision 2105.
Data collection for quantifying immunofluorescence, other than that for WRN and fibrillarin, were acquired using an Opera Phenix HighContent Screening System (PerkinElmer, HH14000000). Micrographic images were acquired using either epifluorescence microscopy or confocal microscopy, which were performed on an Axio Observer.Z1 microscope equipped with an Axiocam 506 mono camera and Apoptome.2 (Carl Zeiss) and a Zeiss LSM 700 laser scanning confocal system equipped with Axio Observer (Carl Zeiss), respectively. For the WRN/Fibrillarin IF, images were obtained via the Zeiss LSM510 Upright Confocal System. For PNA/Telomere FISH: Images were captured with a Nikon Eclipse 80i microscope and processed with software NIS-Elements BR. 30 to 60 metaphases were analyzed for cells of the indicated genotypes.
Data analysis
As described in the methods section, analysis of Project Achilles and Project DRIVE dependency datasets, as well as differential expression analyses, were performed with RStudio (R version 3.4.1), using the following R packages: "Limma", "edgeR", and "fgsea".
For differential expression analysis, we first excluded genes which had less than 1 count per million in more than half of the samples. The weighted trimmed mean of M-values method was used to normalize the library size of each sample, using the calcNormFactors function from the R package: edgeR. To estimate the log-fold change (LFC) effect of WRN knockout on each gene in each cell line we used the R package Limma. Specifically, we fit a linear model for the expression of each gene, using cell line and sgRNA (WRN vs. control) as covariates. Read counts data were transformed using the Limma function 'voom' prior to model fitting, in order to model the meanvariance relationship of the log-counts data. We then extracted LFC effect sizes and empirical-Bayes moderated t-statistics for the WRN knockout effect for each gene and cell line. Gene set enrichment analysis (GSEA) was run to test for gene sets that were up-or downregulated in each cell line after WRN knockout. In particular, we used the R package fgsea to estimate normalized enrichment statistics, and associated P values, for each gene set in the Hallmark Collection from the Molecular Signatures Database. The GSEA algorithm was
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run using t-statistics as the gene-level statistics, 1 million random permutations for each cell line tested, and a "GSEA parameter" of 1.
For all IF other than that for WRN and fibrillarin, images were analyzed on Harmony High Content Imaging and Analysis Software (PerkinElmer, HH17000001). For WRN/Fibrillarin IF: Weighted Pearson colocalization coefficients were calculated by obtaining Z-stacks of 5 representative highpowered fields at 63x magnification and scored via the Zeiss Zen Blue software.
To assess differences between the effect of WRN knockout on IF intensity values (phospho-p53-, p21-, ɣH2AX-and phosphoATMstaining) in MSI versus MSS cell lines, we used a linear model approach. Specifically, linear models were fit to the log-intensity values with guide and cell line intercept terms. Comparisons of the change in log-intensity after WRN knockout between cell lines were then obtained using the 'contrast' function of the R package lsmeans.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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As described in the methods section, all genomic data used in the analysis has been published and can be found in the Cancer Cell Line Encyclopedia (CCLE) portal (https://portals.broadinstitute.org/ccle/data). Cancer cell line genomic data used in the analysis, including gene-level mRNA expression, gene-level relative copy number, and mutation calls, were taken from the DepMap 18Q4 data release. CRISPR dependency data were taken from the 18Q4 Avana dataset Novartis' Project DRIVE be downloaded from Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
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Sample size
All cell lines included in the functional genomic datasets were analyzed unless they were excluded due to indeterminate MSI status. No sample size calculation was performed. The differential WRN dependency between MSI and MSS cell lines was highly significant in two independent large-scale functional genomic datasets, demonstrating that this sample size was sufficient. We validated these results using a smaller sample of these cell lines (6 MSI and 5 MSS cell lines representing at least one cell line from the 4 most common MSI lineages) to confirm that these differences were also present using a single-gene knockout approach, and 5 cell lines per group was more than sufficient for this purpose Data exclusions Cell lines in which MSI status was indeterminate was excluded from the analyses. This exclusion criteria was pre-established.
Replication
With the exception of RNA-seq (which was performed with two biological replicates), all experiments were replicated at least once. All attempts at replication successfully confirmed our findings.
nature research | reporting summary
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Flow Cytometry
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All plots are contour plots with outliers or pseudocolor plots.
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Methodology
Sample preparation
Cells were plated at the following densities in a 12 well plate: KM12-Cas9 -4e5/well SW620-Cas9 -3e5/well ES2-Cas9 -2e5-well OVK18-Cas9 -3e5/well SW48-Cas9 -4e5/well SW837-Cas9 -4e5/well Cells were transduced in media containing polybrene at a final concentration of 4ug/mL: Once viral media was added to the cells, all cells (with the exception of ES2 311Cas9, which shows viral toxicity when spun) were spun for 2 hours at 2000 rpm and 37 degrees celsius. 24 hours post infection, cells were split and were put under puromycin selection (1ug/mL final concentration) The EdU assay was completed on both day 4 and day 7 post infection using the following protocol, adapted from the protocol from the Click-iT™ Plus EdU Flow Cytometry Assay Kit. Cells were pulsed with EdU (5-ethynyl-2'-deoxyuridine) for 2-4 hours (KM12,SW620,ES2 and OVK18 for 2 hours, SW48 and SW837 for 4 hours) at a final concentration of 10uM. After EdU incubation, cells were washed with 1X PBS and trypsinized with 100uL of 0.25% trypsin per well. After ~5 minutes of incubation with trypsin, the appropriate media supplemented with 10% FBS was added to stop trypsinization. Cells were washed once with PBS, once with PBS+1%BSA, and then resuspended in 100uL of fixative and left in the dark for 10-15 minutes at room temperature. Cells were then washed with PBS+1%BSA and resuspended in 100uL of Saponin-based permeabilization and wash buffer. Per sample: 469uL PBS 5uL Copper protectant 1.25uL fluorescent dye picolyl azide 25uL Reaction Buffer Additive (made from 10X Reaction Buffer Additive diluted in deionized water) Sample was incubated in the dark for 30 minutes at room temperature. Samples were then washed with saponin based p&W buffer and then resuspended in 0.2% TritonX with Dapi diluted 1:1000 in PBS. Left in the dark for 10 minutes at room temperature, washed with PBS and then resuspended in 500uL of PBS to be read out via flow cytometry. Serum starvation samples were made by replacing media with serum free media 24 hours before EdU staining, and cells were prepared in the same way for flow cytometry. We also included a no EdU sample. Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
